Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
|Year of publication||2012|
|Type||Article in Periodical|
|Magazine / Source||International Journal of Oncology|
|Field||Oncology and hematology|
|Keywords||breast cancer; HER2 protein; trastuzumab; AKT1 protein; AKT2 protein; prognosis|
|Description||Trastuzumab is effective in about half of HER2- positive breast cancer patients. The PI3K/Akt signalling pathway plays an important role in the process of primary and secondary resistance to anti-HER2 targeted therapy. We evaluated the relationship between expression, activation and subcellular localization of selected Akt isoforms and response to trastuzumab-based anti-HER2 targeted therapy in patients with HER2-positive metastatic breast cancer.|